BACK

news

Sundia congratulates De Novo Pharmatech for SC10914 IND approval in China

2016-09-09

In August 2016, De Novo Pharmatech successfully received their first CFDA IND approval for the class 1.1 IND submission (SC10914) for innovative target therapy in oncology. This is a new target therapy co-submitted by De Novo Pharmatech and Qingfeng Pharmaceutics. Sundia is honored to have contributed to and assisted both companies in conducting part of the pre-clinical pharmacodynamics study as well as facilitating the successful on-site verification by the PFDA.

share this